Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tradr 2X Short TSLA Daily ETF
TSLQ
5
ProShares UltraPro Short S&P500 ETF
SPXU
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.